Choosing Frontline Therapy for Patients With Metastatic Pancreatic Adenocarcinoma
Midhun Malla, MD
Michael A. Morse, MD, FACP, MHS
Benjamin Leon Musher, MD
Janie Y. Zhang, MD
Rahul Gosain, MD, MBA
Rohit Gosain, MD
Key Points
- Frontline clinical trial enrollment should be considered whenever appropriate.
- Triplet chemotherapy regimens may offer survival advantages in carefully selected patients.
- Social factors and functional independence significantly influence treatment tolerability.
- Germline and molecular testing are increasingly important in treatment planning.
At a Clinical Insights discussion coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Brothers podcast cohosts Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, were joined by Midhun Malla, MD, of the University of Alabama; Michael A. Morse, MD, FACP, MHS, of Duke Cancer Center; Benjamin Leon Musher, MD, of Baylor College of Medicine; and Janie Y. Zhang, MD, of the University of Pittsburgh, to explore how clinicians navigate complex frontline treatment decisions in metastatic pancreatic adenocarcinoma.
Dr. Zhang emphasized the importance of considering frontline clinical trial enrollment whenever feasible. Given the historically poor outcomes associated with metastatic pancreatic cancer and the rapid development of novel targeted therapies, clinical trials may provide access to promising agents earlier in the disease course. Outside of a trial setting, Dr. Zhang generally favors triplet chemotherapy regimens for appropriately fit patients. She cited the survival advantage observed with NALIRIFOX (liposomal irinotecan, 5-FU/leucovorin, and oxaliplatin) in NAPOLI 3. However, she emphasized that treatment selection must remain individualized.
The panel highlighted that treatment tolerance is influenced by far more than age or performance status alone. Social support, daily activities, transportation needs, and living arrangements often influence the feasibility of intensive chemotherapy regimens. For some patients, practical considerations such as managing an ambulatory infusion pump may affect treatment selection as much as traditional clinical variables. As a result, gemcitabine plus nab-paclitaxel remains an important frontline option for many patients.
Comprehensive molecular testing was also identified as an increasingly important component of initial evaluation. Universal germline testing, next-generation sequencing, and liquid biopsy can identify actionable alterations and guide treatment planning. In particular, homologous recombination deficiency and BRCA-associated tumors may derive greater benefit from platinum-containing regimens. The panel agreed that integrating molecular profiling into frontline decision-making will play an increasingly central role as targeted treatment options continue to expand.